Alexander Drilon
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Oncology top 0.1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 264
- Lung Cancer Diagnosis and Treatment 25
- Oncology 197
- Colorectal Cancer Treatments and Studies 74
- Lung Cancer Research Studies 54
- Cancer Immunotherapy and Biomarkers 25
- HER2/EGFR in Cancer Research 24
- Co-authors
- Marc Ladanyi (58 shared papers)Emiliano Cocco (8 shared papers)Maurizio Scaltriti (6 shared papers)Maria E. Arcila (41 shared papers)Mark G. Kris (52 shared papers)Natasha Rekhtman (27 shared papers)Charles M. Rudin (35 shared papers)David M. Hyman (43 shared papers)
- Journals
- Journal of Clinical Oncology (114 papers)Annals of Oncology (53 papers)Journal of Thoracic Oncology (36 papers)Cancer Research (27 papers)Clinical Cancer Research (21 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Alexander Drilon
372 papers receiving 13.7k citations
Alexander Drilon's Hit Papers
Peers
Comparison fields: 5 of 128
- Pulmonary and Respiratory Medicine 7.6k
- Oncology 6.3k
- Cancer Research 3.0k
- Pathology and Forensic Medicine 1.5k
- Hepatology 487
Countries citing papers authored by Alexander Drilon
This map shows the geographic impact of Alexander Drilon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Drilon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Drilon more than expected).
Fields of papers citing papers by Alexander Drilon
This network shows the impact of papers produced by Alexander Drilon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Drilon. The network helps show where Alexander Drilon may publish in the future.
Co-authors
The 25 scholars most cited alongside Alexander Drilon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 392 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | NTRK fusion-positive cancers and TRK inhibitor therapy Hit paper breakdown → | 2018 | 1001 |
| 2 | Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping Hit paper breakdown → | 2015 | 438 |
| 3 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 430 |
| 4 | NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls Hit paper breakdown → | 2019 | 381 |
| 5 | 2013 | 354 | |
| 6 | Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions Hit paper breakdown → | 2017 | 346 |
| 7 | Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets Hit paper breakdown → | 2016 | 341 |
| 8 | Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial Hit paper breakdown → | 2016 | 335 |
| 9 | High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden Hit paper breakdown → | 2019 | 309 |
| 10 | 2017 | 288 | |
| 11 | Targeting MET in Lung Cancer: Will Expectations Finally Be MET? Hit paper breakdown → | 2016 | 274 |
| 12 | Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial Hit paper breakdown → | 2022 | 262 |
| 13 | 2019 | 243 | |
| 14 | 2018 | 239 | |
| 15 | 2017 | 239 | |
| 16 | 2020 | 218 | |
| 17 | 2015 | 209 | |
| 18 | 2019 | 208 | |
| 19 | 2020 | 185 | |
| 20 | 2020 | 184 |
About Alexander Drilon
Alexander Drilon is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Surgery, having authored 392 papers that have together received 14.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (264 papers), Cancer Genomics and Diagnostics (98 papers), Colorectal Cancer Treatments and Studies (74 papers), Lung Cancer Research Studies (54 papers), Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Diagnosis and Treatment (25 papers), HER2/EGFR in Cancer Research (24 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (23 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.6k citations), Oncology (6.3k citations), Cancer Research (3.0k citations), Pathology and Forensic Medicine (1.5k citations) and Hepatology (487 citations). Alexander Drilon has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Marc Ladanyi, Emiliano Cocco, Maurizio Scaltriti, Maria E. Arcila, Mark G. Kris, Natasha Rekhtman, Charles M. Rudin, David M. Hyman, Ryma Benayed and Sai‐Hong Ignatius Ou. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.